ACRP CP FINAL EXAM LATEST VERSION 2026-2027 ACTUAL 150
QUESTION AND CORRECT ANSWERS|AGRADE.
What would be the first priority for an investigator when a subject wishes to
withdraw prematurely from the trial?
Correct Answer: Try to obtain the subject's reason for withdrawal.
Expert Rationale:
When a subject expresses a desire to withdraw from a clinical trial prematurely,
the investigator's primary responsibility is to prioritize the subject's safety and
well-being while also gathering critical information. The first priority is to
respectfully inquire about the subject's reasons for withdrawal. Understanding
the rationale—whether related to adverse events, perceived lack of efficacy,
logistical challenges, or other personal reasons—is essential for ensuring
subject safety, maintaining data integrity, and fulfilling regulatory and ethical
obligations. This information may reveal important safety signals, highlight
areas for protocol improvement, and inform the subject's ongoing medical
care. The investigator should document the discussion and ensure the subject
understands that withdrawal will not affect their standard medical care.
A CRO recently switched from a paper CRF to an EDC system. The EDC system
must conform to the established requirements for:
Correct Answer: Validation, accuracy, reliability, completeness.
Expert Rationale:
Electronic Data Capture (EDC) systems used in clinical trials must meet rigorous
regulatory and quality standards to ensure the integrity and credibility of the
data collected. The system must be validated to confirm that it consistently
performs as intended. It must ensure accuracy by correctly recording and
storing data without errors. It must demonstrate reliability through consistent
,performance and uptime. Finally, it must support data completeness by
preventing missing or incomplete data entry. These requirements align with ICH
GCP E6(R2) guidelines and 21 CFR Part 11, which govern electronic records and
signatures. The system must also include audit trails, user access controls, and
robust data backup procedures.
Part of a sponsor's responsibility pertaining to electronic trial data handling is
to:
Correct Answer: Maintain an audit trail, data trail, and edit trail.
Expert Rationale:
Sponsors bear the ultimate responsibility for the integrity of data generated in
clinical trials. This includes ensuring that electronic data handling systems are
compliant with regulatory standards such as 21 CFR Part 11. A critical
component of this is the maintenance of comprehensive audit trails, data trails,
and edit trails. An audit trail documents who accessed the system, when, and
what actions were performed. A data trail provides a complete history of the
data from source to final database. An edit trail records all changes made to
data, including the original value, the new value, the date and time of the
change, and the identity of the person making the change. These trails are
essential for reconstructing the course of events, ensuring data integrity, and
facilitating regulatory inspections.
A research subject's responsibilities for study participation should be
described in the:
Correct Answer: ICF (Informed Consent Form).
Expert Rationale:
The Informed Consent Form (ICF) is the primary document that outlines the
subject's responsibilities and expectations during participation in a clinical trial.
According to ICH GCP E6(R2) and FDA regulations, the ICF must clearly describe
,what will be required of the subject, including the duration of participation, the
number and timing of visits, the procedures to be performed, potential risks
and benefits, and the subject's right to withdraw at any time without penalty.
The ICF also informs subjects of their obligation to adhere to study procedures,
report adverse events, and comply with protocol requirements. By signing the
ICF, the subject acknowledges their understanding of these responsibilities and
voluntarily agrees to participate.
What document would an investigator reference to learn more about the
previous clinical and nonclinical results of studies of the investigational
product (IP)?
Correct Answer: Investigator's Brochure (IB).
Expert Rationale:
The Investigator's Brochure (IB) is a comprehensive document that compiles all
relevant clinical and nonclinical data on an investigational product. It serves as
the primary reference for investigators, providing essential information about
the product's pharmacological properties, toxicology, pharmacokinetics,
pharmacodynamics, and safety profile from preclinical studies and previous
clinical trials. The IB is a critical resource for understanding the product's
potential risks and benefits, designing the study protocol, and making informed
decisions about subject safety. It is updated periodically as new data becomes
available and is a key component of the investigator's toolkit for conducting the
trial in accordance with GCP and regulatory requirements.
During a multi-site clinical study, whose responsibility is it to report subject
recruitment rate?
Correct Answer: The CRA (Clinical Research Associate).
Expert Rationale:
The Clinical Research Associate (CRA) is the sponsor's representative
, responsible for monitoring the progress of a clinical trial at the site level. One
of the CRA's key duties is to track and report subject recruitment rates to the
sponsor. This includes monitoring enrollment progress against the protocol's
recruitment timeline, identifying potential barriers to recruitment, and
communicating any deviations or delays. The CRA ensures that the site is
meeting its enrollment goals and may provide recommendations for
recruitment strategies if needed. While the Principal Investigator (PI) is
responsible for overseeing the site's activities, the CRA is responsible for
reporting recruitment metrics to the sponsor and ensuring that the site's
performance aligns with the study's overall objectives.
An unconscious adult subject was enrolled in a study after obtaining consent
from a Legally Acceptable Representative (LAR), and protocol therapy was
initiated. The subject showed significant improvement in his clinical condition
and regained consciousness. The Investigator should inform the subject about
the study and:
Correct Answer: Obtain consent from the subject for the study.
Expert Rationale:
When a subject who was initially enrolled through a Legally Acceptable
Representative (LAR) regains consciousness and becomes capable of providing
informed consent, the investigator must obtain the subject's own consent to
continue participation in the study. This is a fundamental ethical and regulatory
requirement, as respect for persons—a core principle of the Belmont Report—
dictates that individuals have the right to make their own decisions about
participation when they are capable. The investigator should provide the
subject with a full explanation of the study, including its purpose, procedures,
risks, and benefits, and obtain the subject's written consent. The LAR's prior
consent is no longer sufficient once the subject regains capacity.
QUESTION AND CORRECT ANSWERS|AGRADE.
What would be the first priority for an investigator when a subject wishes to
withdraw prematurely from the trial?
Correct Answer: Try to obtain the subject's reason for withdrawal.
Expert Rationale:
When a subject expresses a desire to withdraw from a clinical trial prematurely,
the investigator's primary responsibility is to prioritize the subject's safety and
well-being while also gathering critical information. The first priority is to
respectfully inquire about the subject's reasons for withdrawal. Understanding
the rationale—whether related to adverse events, perceived lack of efficacy,
logistical challenges, or other personal reasons—is essential for ensuring
subject safety, maintaining data integrity, and fulfilling regulatory and ethical
obligations. This information may reveal important safety signals, highlight
areas for protocol improvement, and inform the subject's ongoing medical
care. The investigator should document the discussion and ensure the subject
understands that withdrawal will not affect their standard medical care.
A CRO recently switched from a paper CRF to an EDC system. The EDC system
must conform to the established requirements for:
Correct Answer: Validation, accuracy, reliability, completeness.
Expert Rationale:
Electronic Data Capture (EDC) systems used in clinical trials must meet rigorous
regulatory and quality standards to ensure the integrity and credibility of the
data collected. The system must be validated to confirm that it consistently
performs as intended. It must ensure accuracy by correctly recording and
storing data without errors. It must demonstrate reliability through consistent
,performance and uptime. Finally, it must support data completeness by
preventing missing or incomplete data entry. These requirements align with ICH
GCP E6(R2) guidelines and 21 CFR Part 11, which govern electronic records and
signatures. The system must also include audit trails, user access controls, and
robust data backup procedures.
Part of a sponsor's responsibility pertaining to electronic trial data handling is
to:
Correct Answer: Maintain an audit trail, data trail, and edit trail.
Expert Rationale:
Sponsors bear the ultimate responsibility for the integrity of data generated in
clinical trials. This includes ensuring that electronic data handling systems are
compliant with regulatory standards such as 21 CFR Part 11. A critical
component of this is the maintenance of comprehensive audit trails, data trails,
and edit trails. An audit trail documents who accessed the system, when, and
what actions were performed. A data trail provides a complete history of the
data from source to final database. An edit trail records all changes made to
data, including the original value, the new value, the date and time of the
change, and the identity of the person making the change. These trails are
essential for reconstructing the course of events, ensuring data integrity, and
facilitating regulatory inspections.
A research subject's responsibilities for study participation should be
described in the:
Correct Answer: ICF (Informed Consent Form).
Expert Rationale:
The Informed Consent Form (ICF) is the primary document that outlines the
subject's responsibilities and expectations during participation in a clinical trial.
According to ICH GCP E6(R2) and FDA regulations, the ICF must clearly describe
,what will be required of the subject, including the duration of participation, the
number and timing of visits, the procedures to be performed, potential risks
and benefits, and the subject's right to withdraw at any time without penalty.
The ICF also informs subjects of their obligation to adhere to study procedures,
report adverse events, and comply with protocol requirements. By signing the
ICF, the subject acknowledges their understanding of these responsibilities and
voluntarily agrees to participate.
What document would an investigator reference to learn more about the
previous clinical and nonclinical results of studies of the investigational
product (IP)?
Correct Answer: Investigator's Brochure (IB).
Expert Rationale:
The Investigator's Brochure (IB) is a comprehensive document that compiles all
relevant clinical and nonclinical data on an investigational product. It serves as
the primary reference for investigators, providing essential information about
the product's pharmacological properties, toxicology, pharmacokinetics,
pharmacodynamics, and safety profile from preclinical studies and previous
clinical trials. The IB is a critical resource for understanding the product's
potential risks and benefits, designing the study protocol, and making informed
decisions about subject safety. It is updated periodically as new data becomes
available and is a key component of the investigator's toolkit for conducting the
trial in accordance with GCP and regulatory requirements.
During a multi-site clinical study, whose responsibility is it to report subject
recruitment rate?
Correct Answer: The CRA (Clinical Research Associate).
Expert Rationale:
The Clinical Research Associate (CRA) is the sponsor's representative
, responsible for monitoring the progress of a clinical trial at the site level. One
of the CRA's key duties is to track and report subject recruitment rates to the
sponsor. This includes monitoring enrollment progress against the protocol's
recruitment timeline, identifying potential barriers to recruitment, and
communicating any deviations or delays. The CRA ensures that the site is
meeting its enrollment goals and may provide recommendations for
recruitment strategies if needed. While the Principal Investigator (PI) is
responsible for overseeing the site's activities, the CRA is responsible for
reporting recruitment metrics to the sponsor and ensuring that the site's
performance aligns with the study's overall objectives.
An unconscious adult subject was enrolled in a study after obtaining consent
from a Legally Acceptable Representative (LAR), and protocol therapy was
initiated. The subject showed significant improvement in his clinical condition
and regained consciousness. The Investigator should inform the subject about
the study and:
Correct Answer: Obtain consent from the subject for the study.
Expert Rationale:
When a subject who was initially enrolled through a Legally Acceptable
Representative (LAR) regains consciousness and becomes capable of providing
informed consent, the investigator must obtain the subject's own consent to
continue participation in the study. This is a fundamental ethical and regulatory
requirement, as respect for persons—a core principle of the Belmont Report—
dictates that individuals have the right to make their own decisions about
participation when they are capable. The investigator should provide the
subject with a full explanation of the study, including its purpose, procedures,
risks, and benefits, and obtain the subject's written consent. The LAR's prior
consent is no longer sufficient once the subject regains capacity.
